Table 1.
HCC with MO |
HCC without MO |
|||||||||||
Case | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 |
Age at Dx of NASH | 73 | 81 | 78 | 71 | 68 | 75 | 71 | 80 | 75 | 78 | 81 | 66 |
Gender | F | M | M | F | M | F | M | F | F | M | M | M |
History of BTF | - | - | - | - | - | - | - | + | - | - | - | - |
BMI (kg/m2) | 31.0 | 26.3 | 25.5 | 32.0 | 26.8 | 23.0 | 27.0 | 32.1 | 34.0 | 23.1 | 24.5 | 25.2 |
T2DM | + | + | + | + | - | + | + | - | + | - | - | - |
Hypertension | + | + | + | + | - | - | - | + | + | - | + | + |
Dyslipidemia | - | - | - | + | - | + | + | + | - | + | + | - |
Varices | - | - | - | - | + | - | + | - | + | - | - | - |
Ascites | - | - | - | - | - | - | - | - | - | - | - | - |
AST (IU/L) | 91 | 67 | 43 | 33 | 34 | 43 | 36 | 34 | 43 | 25 | 83 | 78 |
ALT (IU/L) | 46 | 48 | 49 | 21 | 17 | 32 | 22 | 33 | 40 | 20 | 37 | 75 |
γ-GTP (IU/L) | 122 | 129 | 418 | 72 | 30 | 222 | 46 | 67 | 73 | 104 | 360 | 279 |
Total bilirubin (mg/dL) | 1.0 | 0.7 | 0.8 | 1.1 | 1.4 | 1.1 | 1.5 | 0.6 | 1.2 | 0.6 | 0.6 | 0.8 |
Albumin (g/dL) | 3.8 | 3.7 | 3.4 | 2.9 | 3.3 | 4.0 | 2.9 | 4.1 | 3.7 | 3.8 | 3.4 | 4.2 |
Prothrombin time (%) | 53 | 72 | 97 | 62 | 69 | NAa | 59 | 69 | 86 | 75 | 84 | NAa |
Platelet (× 104/μL) | 21.1 | 12.3 | 10.4 | 11.2 | 4.5 | 14.5 | 6.4 | 31.6 | 11.7 | 12.1 | 26.4 | 11.4 |
Child-Pugh score | A | A | A | B | B | -a | B | A | A | A | A | -a |
HBsAg | - | - | - | - | - | - | - | - | - | - | - | - |
Anti-HBc | + | - | - | + | - | - | - | - | + | + | - | + |
Anti-HCV | - | - | - | - | - | - | - | - | - | - | - | - |
Histological features (Classification by Brunt) | ||||||||||||
Grade | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 2 |
Stage | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 1 | 2 | 4 |
Type of cirrhosis | Mixed | Mixed | Macro | Mixed | Micro | Mixed | Mixed | Mixed | Mixed | - | - | Macro |
AFP (ng/mL) | 11 | 26 | 15 | 25 | 7 | 9 | 3 | 8 757 | 12 | 2 963 | 900 100 | 8 |
DCP (mAU/mL) | 18 | 24 | 20 | 116 | 24 | NAa | 14 | 35 | 907 | 131 | 10 700 | NAa |
Maximum size of HCC (mm) | 35 | 50 | 40 | 28 | 22 | 17 | 50 | 26 | 40 | 40 | 110 | 70 |
Number of HCC | Mul | Mul | Mul | Mul | Mul | Sol | Mul | Sol | Mul | Mul | Mul | Sol |
TNM stage | III | III | III | III | IVA | I | III | II | III | IVB | III | II |
Initial treatment | Ope | TACE | Ope | TACE | TAI | RFA | TACE | TACE | Ope | Chemo | Ope | TAI |
+ RFA | + RFA | + Ope | + RFA | + Ope | ||||||||
Outcome | Alive | Dead | Dead | Alive | Alive | Alive | Alive | Alive | Dead | Dead | Alive | Alive |
Cause of death | - | LR | NLR | - | - | - | - | - | LR | LR | - | - |
Follow-up period after Dx of HCC (days) | 2 599 | 1 706 | 288 | 1 140 | 280 | 1 011 | 687 | 2 198 | 1 525 | 489 | 162 | 330 |
HCC: hepatocellular carcinoma; MO: multicentric occurrence; Dx: diagnosis; BTF: blood transfusion; BMI: body mass index; M: Male; F: Female; T2DM: type 2 diabetes mellitus; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltranspeptidase; NA: not available; AFP: alpha-fetoprotein; DCP: des-γ-carboxy-prothrombin; Mixed: mixed nodular cirrhosis; Macro: macronodular cirrhosis; Micro: micronodular cirrhosis; Mul: multiple; Sol: solitary; TACE: transcatheter arterial chemoembolization; TAI: transcatheter arterial infusion chemotherapy; RFA: radiofrequency ablation; Ope: operation; LR: liver-related death; NLR: non-liver-related death;
An oral administration of warfarin prevented the evaluation.